Apollo Endosurgery (DB:HQ8F) - Aktienkurs, Nachrichten und Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

HQ8F Aktienübersicht

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy.

Über das Unternehmen

HQ8F grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

Revenue is forecast to grow 31.98% per year

Risikoanalyse

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Apollo Endosurgery, Inc. Wettbewerber

Stratec

XTRA:SBS

€529.4m

Eckert & Ziegler

XTRA:EUZ

€933.5m

Drägerwerk KGaA

XTRA:DRW3

€823.2m

PULSION Medical Systems

MUN:PUS

€131.9m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Apollo Endosurgery
Historische Aktienkurse
Aktueller Aktienkurs	US$9.10
52-Wochen-Hoch	US$9.64
52-Wochen-Tief	US$3.39
Beta	2.32
11 Monat Veränderung	-0.85%
3 Monate Veränderung	-1.88%
1 Jahr Veränderung	70.35%
33 Jahre Veränderung	386.63%
5 Jahre Veränderung	92.80%
Veränderung seit IPO	-49.11%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	HQ8F	DE Medical Equipment	DE Markt
7D	1.0%	3.6%	1.5%
1Y	70.3%	3.6%	12.6%

Rendite im Vergleich zur Industrie: HQ8F exceeded the German Medical Equipment industry which returned -7% over the past year.

Rendite vs. Markt: HQ8F exceeded the German Market which returned -8.6% over the past year.

Preisvolatilität

Is HQ8F's price volatile compared to industry and market?
HQ8F volatility
HQ8F Average Weekly Movement	1.4%
Medical Equipment Industry Average Movement	5.0%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.7%
10% least volatile stocks in DE Market	2.4%

Stabiler Aktienkurs: HQ8F has not had significant price volatility in the past 3 months.

Volatilität im Zeitverlauf: HQ8F's weekly volatility has decreased from 12% to 1% over the past year.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2005	202	Chas McKhann	www.apolloendo.com

Apollo Endosurgery, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Apollo Endosurgery im Vergleich zum Marktanteil des Unternehmens?
HQ8F grundlegende Statistiken
Marktanteil	€531.72m
Gewinn(TTM)	-€36.54m
Umsatz(TTM)	€70.49m

7.5x

Kurs-Umsatz-Verhältnis

-14.6x

Kurs-Gewinn-Verhältnis

Ist HQ8F zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
HQ8F Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$76.86m
Kosten der Einnahmen	US$34.43m
Bruttogewinn	US$42.43m
Sonstige Ausgaben	US$82.27m
Umsatz	-US$39.84m

Zuletzt gemeldete Gewinne

Dec 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.69
Bruttomarge	55.20%
Nettogewinnspanne	-51.84%
Schulden/Eigenkapital-Verhältnis	164.7%

Wie hat sich HQ8F auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company listing is no longer active

HQ8F Aktienübersicht

Belohnungen

Risikoanalyse

Apollo Endosurgery, Inc. Wettbewerber

XTRA:SBS

€529.4m

XTRA:EUZ

€933.5m

XTRA:DRW3

€823.2m

MUN:PUS

€131.9m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Full year 2022 earnings released: US$0.98 loss per share (vs US$0.82 loss in FY 2021)

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.23 loss in 3Q 2021)

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Recent updates

Full year 2022 earnings released: US$0.98 loss per share (vs US$0.82 loss in FY 2021)

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.23 loss in 3Q 2021)

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Second quarter 2022 earnings released: US$0.26 loss per share (vs US$0.11 loss in 2Q 2021)

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.17 loss in 1Q 2021)

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought €206k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Apollo Endosurgery, Inc. Announces Board Changes

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold €432k worth of stock

Chief Financial Officer recently bought €186k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Insider recently sold €105k worth of stock

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

New 90-day high: €6.05

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Revenue beats expectations

Insider recently bought €70k worth of stock

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought €121k worth of stock

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: €3.76

New 90-day high: €2.00

Revenue beats expectations

Third quarter 2020 earnings released: US$0.11 loss per share

New 90-day high: €1.51

New 90-day low - €1.13

New 90-day low - €1.20

First half earnings released

Apollo Endosurgery, Inc. announced that it expects to receive $25 million in funding

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Apollo Endosurgery, Inc.'s Grundlagenzusammenfassung

7.5x

-14.6x

Erträge &amp; Einnahmen

Erträge & Einnahmen